VGN50
£175.00 1mg
Blocks MYC activation.
VGN50 is a peptide derived from the Kaposi’s sarcoma-associated herpes virus transactivator (K-Rta) sequence, based on the
binding interface of K-Rta and cellular coactivators. VGN50 interacts with components of coactivators including nuclear receptor coactivator 2 (NCOA2), p300, and SWItch/Sucrose Non-Fermentable (SWI/SNF), the subfamily of ATP-dependent chromatin remodelling complex proteins. VGN50 blocks recruitment of the SWI/SNF complex and results in downregulation of both MYC and MYC-target gene transcription. Expression of MYC is tightly regulated in normal cells but becomes dysregulated in many types of human cancer cells, and application of VGN50 can reduce cell proliferation and selectively kill cancer cell lines in both tissue culture and a xenograft tumour mouse model.
Please contact us for availability.
Additional information
| Other Names | K-Rta Peptide 1, Virus de Gann wo Naosu ORF50, K-Rta peptide |
|---|---|
| Three Letter Sequence | H-(D)Arg-Lys-Lys-Arg-Arg-Orn-Arg-Arg-Arg-?Ala-Leu-Ser-Ser-Ile-Leu-Gln-Gly-Leu-Tyr-Gln-Leu-Asp-Thr-OH |
| Molecular Weight | 2827.7 |
| Molecular Formula | C121H218N46O32 |
| Sequence | rKKRR-Orn-RRR-?Ala-LSSILQGLYQLDT |
| Solubility | Soluble in water |
| Appearance | Freeze dried solid |
| Storage | Store dry, frozen and in the dark |
| Purity | >95% by HPLC |
| Modifications | D arginine at position 1, ornithine at position 6 and beta alanine at position 10 |
| Searchable Words | VGN50, VGN 50, PP-320, PP320, K-Rta Peptide 1, Virus de Gann wo Naosu ORF50, rKKRR-Orn-RRR-?Ala-LSSILQGLYQLDT |